The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

Unemployed people will be given weight-loss jabs under Government plans to get them back to work. Wes Streeting, the Health ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Hims & Hers Health saw its shares surge by 7% today after the FDA announced that it would reconsider its decision to limit ...

周一，BTIG重申了对LifeMD Inc (NASDAQ: LFMD)的信心，维持买入评级和12.00美元的目标价。这一背书是在涉及二甲双胍（tirzepatide）的法律案件最新进展中做出的。二甲双胍是一种用于治疗2型糖尿病和肥胖症的药物。一位联邦法官批准了食品和药品管理局（FDA）的自愿撤回和暂缓请求，允许复方药房在FDA进行审查期间继续在特定条件下配发复方二甲双胍。 FDA已获得时间进行审 ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might ...

The FDA's decision came in response to a lawsuit filed in federal court in Fort Worth, Texas, by the Outsourcing Facilities Association, a trade association focused on ensuring access to compounded ...